Analysis of hepatitis C virus RNA prevalence and surrogate markers of infection among seropositive voluntary blood donors
β Scribed by Joseph M. Romeo; Paul P. Ulrich; Michael P. Busch; Girish N. Vyas
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 970 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Hepatitis C virus (HCV) is the predominant cause of parenterally transmitted non-A, non-B (NANB) hepatitis worldwide (1, 2). Although the clinical manifestations of acute HCV infection are often relatively mild, persistent infection is a frequent outcome and is associated with significant risk of progression to chronic liver
π SIMILAR VOLUMES
Approximately 90% of subjects with chronic hepatitis resulting from hepatitis C virus infection have hepatitis C virus RNA in serum. However, the prevalence of hepatitis C virus RNA in serum from subjects with hepatitis C virus antibody associated with persistent normal liver biochemical values is u
A high prevalence of anti-Cl00-3 antibodies has been reported in chronic hemodialysis patients. It is, however, unclear whether the results reflect true hepatitis C virus (HCV) infection in these patients, since false-positive results have been reported with this antibody assay. In the present study
## Abstract Serum samples from 1,765 consecutive Sardinian blood donors, negative for hepatitis B surface antigen (HBsAg) and for antibodies to human immunodeficiency virus (HIV) (antiβHIV), were evaluated for the presence of antibodies to hepatitis C virus (antiβHCV) by secondβgeneration ELISA. An
An enzyme immunoassay (EIA) was developed in-house for the detection of anti-hepatitis C virus (HCV) antibody against the prevailing genotypes in India. The specific reactivity of the test was compared with commercial second and third-generation EIAs and reverse transcription nested polymerase chain
## Abstract It is not known whether there is a trend of increasing or decreasing incidence of new hepatitis C virus (HCV) infections in Japan. From the treatment point of view, it is important to verify HCV genotypes and the prevalence of treatmentβresistant clones of HCV. At the Japanese Red Cross